glp-1 thyroid cancer risk More good data on for those taking meds. Retrospective data but reassuring Currently GLP1s have a warning

ZLZ PeptideRetatrutide ZLZ Peptide Retatrutide is high-scoring but not clean, with intermittent purity misses, major fill outliers (+66%, -66%), and one failed-identity/0 mg result

A lot of people are deterred from securing treatment because of the GLP-1 price tag

IL6 signalling in exercise and disease

And discussing strategies to manage insurance-mandated changes in treatment infringes on clinical care

Lilly must also carry out a milk-only lactation study in lactating women who have received a dose of Foundayo to assess concentrations of orforglipron in breast milk, according to the FDA

No Certainty Theres a lot of uncertainty with these estimates, which CBO admits